CorMedix's Rezzayo Achieves Positive Phase III Results, Boosting Future Revenue Potential
CRMD sits 30% above its 52-week low of $6.125 on elevated volume (3.3× avg).
Summary
CorMedix announced positive topline Phase III ReSPECT results for its drug candidate, REZZAYO, for prophylaxis in adult allogeneic HSCT patients. This significant clinical milestone de-risks the drug and establishes long-term revenue potential, with an sNDA filing planned for H2 2026 and a targeted launch in 2027. The company also reported Q1 2026 product sales of $24.4 million, primarily from the Melinta portfolio, which was previously disclosed in the 8-K and 10-Q filings on May 14. While DefenCath sales continue, the upcoming expiration of TDAPA reimbursement is a known factor. The positive Phase III data for Rezzayo is a major catalyst for the stock, shifting focus to regulatory approval and commercialization.
At the time of this announcement, CRMD was trading at $7.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $621.9M. The 52-week trading range was $6.13 to $17.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.